ARS Pharmaceuticals, Inc - Asset Resilience Ratio
ARS Pharmaceuticals, Inc (SPRY) has an Asset Resilience Ratio of 62.16% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ARS Pharmaceuticals, Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how ARS Pharmaceuticals, Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of ARS Pharmaceuticals, Inc.
Liquid Assets Composition Over Time
This chart breaks down ARS Pharmaceuticals, Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read SPRY total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $203.67 Million | 62.16% |
| Total Liquid Assets | $203.67 Million | 62.16% |
Asset Resilience Insights
- Very High Liquidity: ARS Pharmaceuticals, Inc maintains exceptional liquid asset reserves at 62.16% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ARS Pharmaceuticals, Inc Industry Peers by Asset Resilience Ratio
Compare ARS Pharmaceuticals, Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for ARS Pharmaceuticals, Inc (2021–2025)
The table below shows the annual Asset Resilience Ratio data for ARS Pharmaceuticals, Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 62.16% | $203.67 Million | $327.65 Million | -12.79pp |
| 2024-12-31 | 74.95% | $263.20 Million | $351.15 Million | +7.46pp |
| 2023-12-31 | 67.49% | $157.39 Million | $233.19 Million | +44.80pp |
| 2022-12-31 | 22.69% | $63.86 Million | $281.44 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $61.45 Million | -- |
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is … Read more